Medical News / AAAAI Congress 2021: Sublingual Immunotherapy May Provide Peanut Allergy Desensitization in Toddlers

Sustained unresponsiveness, a pivotal, sought-after benchmark in allergic immunotherapy research, may be achievable with early initiation of peanut sublingual immunotherapy designed to desensitize children with peanut allergy. In late-breaking data presented during the American Academy of Allergy & Immunology (AAAAI) 2021 Virtual Sessions, a team of North Carolina and Texas investigators reported findings showing a dozen toddlers to have undergone sublingual immunotherapy for a peanut allergy were able to pass a sustained unresponsiveness food challenge after 3 years of care. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Omalizumab (Xolair) benefitted sleep disturbance among patients with nasal polyposis over a span of 76 weeks, ... read more
As covered by Lakiea Wright, MD, in a previous interview segment with HCPLive® during the American ... read more
A collection of articles published at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 ... read more
At the American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 Virtual Sessions this weekend, a ... read more